1. 179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT). (December 2022) Authors: Forster, M.D.; Cave, J.; Greystoke, A.; Plummer, R.; Spicer, J.; Thistlethwaite, F.; Turajlic, S.; Craig, A.; Newton, K.; Saggese, M.; Quezada, S.; Peggs, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer. Issue 8 (August 2020) Authors: Harrington, K.J.; Bhide, S.A.; Forster, M.D.; Good, J.S.; Gunn, L.; Kong, A.; Melcher, A.A.; Metcalf, R.; Nenclares, P.; Newbold, K.L.; Nutting, C.M.; Prestwich, R.; Sacco, J.J.; Soliman, H.; Wong, K.H. Journal: Clinical oncology Issue: Volume 32:Issue 8(2020) Page Start: 490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. (August 2018) Authors: Dillon, M.T.; Boylan, Z.; Smith, D.; Guevara, J.; Mohammed, K.; Peckitt, C.; Saunders, M.; Banerji, U.; Clack, G.; Smith, S.A.; Spicer, J.F.; Forster, M.D.; Harrington, K.J. Journal: Clinical and translational radiation oncology Issue: Volume 12(2018) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗